T Cell News and Research

Latest T Cell News and Research

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced results today from its Phase I extension study with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

5 Jun 2012

Exelixis reports data from cabozantinib phase 3 trial on MTC

Exelixis, Inc. today reported data from the phase 3 pivotal trial of cabozantinib in patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).

5 Jun 2012

Researchers uncover cellular basis for age-related breast cancer vulnerability

It is well-known that the risks of breast cancer increase dramatically for women over the age of 50, but what takes place at the cellular level to cause this increase has been a mystery. Some answers and the possibility of preventative measures in the future are provided in a new study by researchers at the U.S. Department of Energy (DOE)'s Lawrence Berkeley National Laboratory.

5 Jun 2012

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

OncoGenex Pharmaceuticals, Inc. announced today data from a Phase 2 study of its investigational compound OGX-427 in chemotherapy-naive metastatic castration resistant prostate cancer (mCRPC) patients will be presented during an oral presentation at the 2012 American Society of Clinical Oncology (ASCO) annual meeting on Tuesday, June 5.

5 Jun 2012

$Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML$

Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML

Astellas Pharma Inc. and Ambit Biosciences Corporation today announced the initiation of a Phase 2b open-label clinical trial of quizartinib as monotherapy in patients with relapsed and refractory acute myeloid leukemia (AML) with FLT3-ITD mutations.

5 Jun 2012

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Oncothyreon Inc. today announced that data from two clinical trials of PX-866, a pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

4 Jun 2012

New data from ImmunoGen’s SAR3419 Phase I study on CD19+ NHL

ImmunoGen, Inc., a biotechnology company, today announced the presentation of new clinical data for the investigational compound, SAR3419, at the American Society of Clinical Oncology (ASCO) annual meeting taking place in Chicago, IL.

4 Jun 2012

High levels of antibody molecule linked to increased rates of death from all diseases

Mayo Clinic researchers have identified an immune system deficiency whose presence shows someone is up to four times likelier to die than a person without it. The glitch involves an antibody molecule called a free light chain; people whose immune systems produce too much of the molecule are far more likely to die of a life-threatening illness such as cancer, diabetes and cardiac and respiratory disease than those whose bodies make normal levels. The study is published in the June issue of Mayo Clinic Proceedings.

4 Jun 2012

CTI acquires world-wide rights to S*BIO’s pacritinib

Cell Therapeutics, Inc., announced today that it has completed its acquisition gaining world-wide rights to S*BIO Pte Ltd.'s pacritinib.

4 Jun 2012

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced results from the trastuzumab emtansine Phase III EMILIA trial conducted by Roche.

4 Jun 2012

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Seattle Genetics, Inc. today announced that data from several clinical trials of ADCETRIS (brentuximab vedotin) will be presented at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2012 in Chicago, IL.

4 Jun 2012

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced final results from a randomized, placebo-controlled, double-blind, phase 2 clinical trial with the selective MET inhibitor tivantinib as a single-agent, investigational, second-line treatment in hepatocellular carcinoma (HCC).

4 Jun 2012

Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cancer

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced that Roche is implementing a "three-pronged approach" to developing trastuzumab emtansine (T-DM1) for early stage HER2-positive breast cancer, according to plans outlined by Roche at its 2012 ASCO analyst event.

4 Jun 2012

Interim results from Bristol-Myers Squibb’s BMS-936558 Phase 1 study on NSCLC, MM and RCC

Bristol-Myers Squibb Company today announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with previously-treated non small-cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma (RCC).

4 Jun 2012

Study reveals why GBM is highly resistant to current chemotherapies

New research from the University of Wisconsin-Madison explains why the incurable brain cancer, glioblastoma multiforme (GBM), is highly resistant to current chemotherapies.

2 Jun 2012

New evidence of important role of next-generation sequencing in cancer treatment

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced results from two studies using next-generation sequencing (NGS) to provide actionable information about genomic tumor alterations in individual patients' cancers across all solid tumor types.

2 Jun 2012

Innovative strategy for regenerating skeletal muscle tissue

An innovative strategy for regenerating skeletal muscle tissue using cells derived from the amniotic fluid is outlined in new research published by scientists at the UCL Institute of Child Health.

2 Jun 2012

Researchers uncover fundamental properties of key molecular signaling system using optical tweezers

By using a laser microbeam technology called optical tweezers, UC Irvine and UCLA researchers have uncovered fundamental properties of a key molecular signaling system involved with development, cancer and cardiovascular disease.

2 Jun 2012

NIH awards $1.9M grant to study genetic control of cell migration

Developmental biologists Dominique Alfandari and Hélène Cousin at the University of Massachusetts Amherst recently received a five-year, $1.9 million grant from the U.S. National Institutes of Health to investigate craniofacial development in a frog model to better understand genetic control of cell migration.

2 Jun 2012

Engineered proteins demonstrate flu-fighting potency

Computer-designed proteins are under construction to fight the flu. Researchers are demonstrating that proteins found in nature, but that do not normally bind the flu, can be engineered to act as broad-spectrum antiviral agents against a variety of flu virus strains, including H1N1 pandemic influenza.

2 Jun 2012

T Cell News and Research

Latest T Cell News and Research

Alnylam announces results from ALN-VSP Phase I study on liver cancers

Exelixis reports data from cabozantinib phase 3 trial on MTC

Researchers uncover cellular basis for age-related breast cancer vulnerability

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

Ambit, Astellas commence quizartinib Phase 2b trial in relapsed/refractory AML

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

New data from ImmunoGen’s SAR3419 Phase I study on CD19+ NHL

High levels of antibody molecule linked to increased rates of death from all diseases

CTI acquires world-wide rights to S*BIO’s pacritinib

ImmunoGen reports data from T-DM1 Phase III trial on HER2-positive metastatic breast cancer

Data from several clinical trials of ADCETRIS to be presented at ASCO annual meeting

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cancer

Interim results from Bristol-Myers Squibb’s BMS-936558 Phase 1 study on NSCLC, MM and RCC

Study reveals why GBM is highly resistant to current chemotherapies

New evidence of important role of next-generation sequencing in cancer treatment

Innovative strategy for regenerating skeletal muscle tissue

Researchers uncover fundamental properties of key molecular signaling system using optical tweezers

NIH awards $1.9M grant to study genetic control of cell migration

Engineered proteins demonstrate flu-fighting potency

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

T Cell News and Research

Latest T Cell News and Research

Immunology eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in